Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 33

Results For "Ltd"

857 News Found

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
Diagnostic Center | February 13, 2024

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr

These re-agent and diagnostic test kits come with 99.7% accuracy


Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
News | February 10, 2024

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024


Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
News | February 10, 2024

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis


Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
News | February 09, 2024

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore


MIRA Pharmaceuticals announces collaboration with Pharmaseed
News | February 08, 2024

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024


IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
News | February 07, 2024

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM


Dr Lal Path Labs posts Q3 FY24 consolidated PAT at Rs. 81.3 Cr
News | February 03, 2024

Dr Lal Path Labs posts Q3 FY24 consolidated PAT at Rs. 81.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023


Industry’s reaction to Union Budget 2024-25
Policy | February 02, 2024

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry


Glenmark partners Pfizer to launch Abrocitinib in India
Drug Approval | February 01, 2024

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India